NPS regains worldwide rights from Takeda for key assets
This article was originally published in Scrip
Executive Summary
NPS Pharmaceuticals will transfer stock valued at $50 million to Takeda Pharmaceutical in exchange for full control of Gattex (teduglutide), which was approved last year in the US and EU to treat adults with short bowel syndrome, and the hypoparathyroidism therapeutic candidate Natpara (recombinant human parathyroid hormone 1-84 or PTH1-84).